$AXON

SMITH PATRICK W sold $6.4M of AXON

SMITH PATRICK W (CHIEF EXECUTIVE OFFICER) sold 10,000 shares of AXON ENTERPRISE, INC. (AXON) at an average of $643.79 ($626.78–$662.70, $6.44M total) across 26 trades on 2026-07-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · SMITH PATRICK W
Published Jul 9, 2026, 9:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 9, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AXON
Neutral
medium confidence
Mentioned
$AXON
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AXONNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around Axon, but without any accompanying earnings, guidance, legal, or product catalyst, the decision value is limited.

02

Market read

A new, primary-source insider sale disclosure for Axon, with 10b5-1 pre-arrangement noted, implying routine execution rather than new negative information.

03

What to watch

The filing does not disclose reasons for the sale, and the net holdings after the transaction remain very large (3.04M shares), which can mute the signal.

Relevance 5/10Novelty 6/10Timing: after-hours, new SEC Form 4 disclosure filed 2026-07-09

Background

The filing is an SEC Form 4 insider transaction by Axon’s CEO, reported as an open-market sale executed across 26 trades.

Company-level read

Ticker impact

$AXONNeutralMedium confidence
Context

Axon CEO Smith Patrick W sold about 10,000 shares in an open-market transaction totaling $6.44M, per a fresh SEC Form 4 filed today.

Expected impact

Likely limited immediate price impact; any reaction should be modest unless accompanied by other company-specific news.

Evidence & confidence

The article provides a primary-source Form 4 with transaction size and pricing range, but no accompanying operational or guidance change. The presence of a 10b5-1 plan suggests routine execution rather than new negative information.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

The sale may be purely liquidity-driven and scheduled under a 10b5-1 plan, so it should not be treated as a bearish fundamental signal.

Key entities

  • AXON ENTERPRISE, INC.

    Subject of the Form 4 insider sale by its CEO.

  • SMITH PATRICK W

    Chief Executive Officer who sold shares totaling $6.44M.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AXONMedAI 8/10

Axon’s AI Era Revenue Jumped Nearly 700%. Here’s What’s Behind It

Axon Enterprise (AXON) reported 35% revenue growth to $904M, beating estimates. AI Era revenue surged nearly 700% YoY. Management raised full-year guidance to 32-34% growth. Gross margin slipped 40 basis points to 62.9%. Analysts estimate a target price of $714, implying 13.7% upside over 2.4 years. The stock trades at 70x forward earnings, with growth driven by software and AI products.

$BABAHighAI 8/10

Breakfast News: Alibaba's AI Push Comes at a Cost

Alibaba's Q1 revenue rose 9% to $39.6B, but operating income fell 57% due to tech investments. BILL Holdings reported 14% revenue growth and 80% operating income increase. U.S. debt surpassed $40T, with Treasury buybacks easing yield pressure. Apple plans 2027 launch for camera AirPods. Axon Enterprise passes competitive position tests, with a 69% potential upside to $1,088.08.

$AXONMed

Axon Stock Rebounds As Its Margin Squeeze Looks Like The Price Of Growth

Axon Enterprise (AXON) shares rose 9.3% on Friday after a 14.3% drop the prior session following its Q2 2026 results. The quarter showed revenue of $904 million, up 35% year over year, and a raised full-year outlook. The market disagreed over margin compression tied to higher memory costs and counter-drone hardware mix, with Axon expecting Q3 adjusted EBITDA margin to hold and rebuild in Q4.

$AXONMed

Raise. So Why Is the Stock Down?

Axon Enterprise (NASDAQ: AXON) reported Q2 revenue of $904M, up 35% year over year, beating estimates of $876.5M. Adjusted EBITDA rose 40% to $242M, and adjusted EPS was $1.88 vs $1.84 expected. Axon raised full-year revenue guidance to 32%-34% growth but reduced software and services gross margin and withdrew operating cash flow and free cash flow guidance.